BioVie IncNASDAQ BIVI Stock Report

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company is headquartered in Carson City, Nevada and currently employs 13 full-time employees. The company went IPO on 2014-01-14. The firm is developing drug therapies to treat chronic debilitating conditions, including liver disease and neurological and neuro-degenerative disorders and certain cancers. In liver disease, the Company's orphan drug candidate BIV201 (continuous infusion terlipressin) is developed as a future treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), hepatitis, and alcoholism. The firm is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.